Sponsor

Probelte Pharma S.L.

Spain Calle Antonio Belmonte Abellan 7, 30100 Murcia, Spain

About the sponsor

Probelte Pharma S.L. focuses on allergen immunotherapy for allergic rhinoconjunctivitis, with research centered on grass pollen and house dust mite sensitisation. Its clinical programme includes subcutaneous immunotherapy approaches for patients with respiratory allergy symptoms linked to environmental allergens.

Grass pollen allergy
House dust mite allergy
Allergic rhinoconjunctivitis

The sponsor’s trials also address patients with allergic rhinoconjunctivitis associated with asthma, reflecting interest in upper and lower airway allergic disease.

About Specializations

Probelte Pharma S.L. runs clinical trials in conditions such as Mite allergy, Seasonal allergy, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

5 clinical trials

Mite allergy

Recruiting

Study on the Effectiveness and Safety of Beltavac for Patients with Allergic Rhinitis from House Dust Mites

Investigational

Study on the Effectiveness and Safety of Beltavac for Patients with Allergic Rhinitis from House Dust Mites

Investigational

Spain

Participants:0–17 years · 18–64 years
Substances:Mixture Of Allergen Extracts Of Dermatophagoides Pteronyssinus And Dermatophagoides Farinae Polymerized With Glutaraldehyde
Sponsor:Probelte Pharma S.L.

Contact Research Centre

Seasonal allergy

Not yet recruiting

Study on the Effectiveness of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis and Possible Asthma

Registered drug

Study on the Effectiveness of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis and Possible Asthma

Registered drug

Poland

Participants:18–64 years
Substances:Placebo
Sponsor:Probelte Pharma S.L.

Contact Research Centre

Mite allergy

Not yet recruiting

Efficacy of subcutaneous modified dust mite allergen extract in adults and children with allergic rhinitis/rhinoconjunctivitis due to house dust mites

Registered drug

Efficacy of subcutaneous modified dust mite allergen extract in adults and children with allergic rhinitis/rhinoconjunctivitis due to house dust mites

Registered drug

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Allergen extracts
Sponsor:Probelte Pharma S.L.

Contact Research Centre

Mite allergy

Not yet recruiting

Standardization of Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts and histamine dihydrochloride in skin testing for patients with dust mite allergy

Registered drugNo placebo